FGFR2 and intrahepatic cholangiocarcinoma: Recently, the US Food and Drug Administration (FDA) has approved infigratinib (BGJ398) and pemigatinib in intrahepatic cholangiocarcinoma with FGFR2 fusions, as well as erdafitinib in advanced urothelial cancer with FGFR2/3 alterations22,23.